• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    PMGC Holdings Signs Non-Binding Letter of Intent to Acquire Majority Stake in U.S.-Based Precision Machining Manufacturing Company Serving Aerospace, Space, Defense, and Semiconductor Markets

    6/1/26 7:31:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAB alert in real time by email
    • The current Letter of Intent is non-binding and contemplates an all-cash acquisition of a 76% interest in the target company
    • Target company is AS9100 compliant, ISO 9001:2015 certified, and ITAR registered, positioning it within highly regulated aerospace, space and defense supply chains
    • Acquisition advances PMGC's stated roll-up strategy in U.S.-based manufacturing amid reshoring and domestic supply chain tailwinds

    NEWPORT BEACH, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC", the "Company", "we" or "us"), a diversified public holding company currently executing a targeted roll-up strategy across U.S.-based manufacturing, today announced that it has entered into a non-binding letter of intent (the "LOI") to acquire a seventy-six percent (76%) controlling interest in a privately held, Arizona based U.S.-based precision machining and contract manufacturing company (the "Target"). The transaction (the "Transaction") would result in the Target's existing owners retaining a 24% minority interest following closing. Based on unaudited financial information provided to PMGC by the Target, the Target generated approximately $5.46 million in revenue and approximately $1.05 million in EBITDA for fiscal year 2025.

    The LOI provides PMGC with a defined exclusivity period, during which the Target and its representatives may not solicit or negotiate competing offers, providing the Company with a protected window to complete confirmatory due diligence and negotiate definitive documentation.

    Founded in 2006, the Target is a precision machining contract manufacturer specializing in high-tolerance, multi-axis CNC machining, including Swiss machining, multi-axis milling, and multi-tasking turning of complex metal and plastic components. The Target has operated for nearly two decades and machines a broad range of materials, including aluminum, brass, stainless steel, titanium, Inconel, and engineered plastics, supported by value-added capabilities, such as laser marking, ultrasonic cleaning, microscopic deburring and microblasting, coordinating measuring machine (CMM) inspection, and performing light assembly.

    The Target serves a diversified base of long-tenured industrial and commercial customers across the aerospace, space, defense, flow control, semiconductor, medical device, and equipment manufacturing sectors, with average customer relationships spanning approximately a decade and a majority of revenue derived from repeat and long-term customers. This recurring revenue profile, combined with a multi-year order backlog, provides meaningful visibility into future work. The Target maintains AS9100 compliance, ISO 9001:2015 certification, and ITAR registration, qualifying it to serve stringent, highly regulated aerospace, space, and defense programs where precision Swiss machining capacity is in structurally short supply.

    As represented by the Target's management, the business generated an adjusted EBITDA margin of over 20% on a trailing-twelve-month basis, reflecting the high value-add nature of its precision manufacturing operations, disciplined cost build-up pricing, and a digitally enabled production and tooling infrastructure. The Target's aerospace and defense end-market exposure has grown substantially in recent years, rising from a single-digit share of revenue to more than 30%, consistent with broader industry demand for domestically produced, high-precision components.

    Transaction Overview

    Under the terms of the LOI, PMGC would acquire a 76% controlling interest in the Target for cash, with the Target's existing owners retaining the remaining 24% interest. The proposed consideration for this interest is subject to confirmatory due diligence. The LOI is non-binding, except with respect to customary provisions regarding exclusivity, confidentiality, expenses, and governing law, and completion of the Transaction is subject to customary closing conditions, including the negotiation and execution of a definitive purchase agreement, the completion of a financial statement audit of the Target, and applicable board and regulatory approvals. There can be no assurance that the Transaction will be completed on the terms described herein, or at all.

    The proposed Transaction is consistent with PMGC's stated strategy of building a vertically integrated U.S.-based precision manufacturing platform through disciplined, accretive acquisitions. The Target would complement the Company's existing precision manufacturing capabilities through its subsidiaries, AGA Precision Systems, SVM Machining, and A&B Aerospace, expanding PMGC's aggregate machining capacity, end-market diversification, and addressable market across the commercial aerospace, space, defense, and broader industrial supply chains. The Target's specialized CNC Swiss machining capabilities, certifications, and established, long-cycle customer relationships are high-barrier-to-entry assets that are difficult to replicate and well aligned with national reshoring and domestic supply chain security priorities.

    If consummated, the Transaction would further diversify PMGC's consolidated revenue base across the aerospace, defense, semiconductor, and industrial sectors, and would add a profitable, cash-generative manufacturing business with recurring revenue and strong backlog visibility. The Company expects the Target's operations to benefit from integration with PMGC's centralized corporate and operating infrastructure, as well as cross-selling opportunities across the Company's existing manufacturing customer relationships.

    Next Steps to Close

    We are currently engaging our auditors to begin a 2-year historical financial audit and interim review of 2026 financial records of the target-to-target completion and closing before Q4 2026. We cannot assure that the US GAAP audit can be completed and the closing will occur, or that audited financial statements will not significantly differ from the unaudited financial statements provided by the Target to us.

    About PMGC Holdings Inc.

    PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "believes," "expects," "plans," "potential," "would" and "future" or similar expressions such as "look forward" are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC's filings with the United States Securities and Exchange Commission ("SEC"), including the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

    IR Contact: IR@pmgcholdings.com



    Primary Logo

    Get the next $ELAB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ELAB
    SEC Filings

    View All

    PMGC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - PMGC Holdings Inc. (0001840563) (Filer)

    6/5/26 4:01:25 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PMGC Holdings Inc. (0001840563) (Filer)

    5/13/26 6:05:52 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by PMGC Holdings Inc.

    PRE 14A - PMGC Holdings Inc. (0001840563) (Filer)

    5/4/26 5:14:14 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NorthStrive Defense Tech Executes Binding Agreement to Acquire Exclusive License to Patented Multi-Domain Drone Payload Technology for Defense, Aerospace and Maritime Applications

    Binding term sheet for an exclusive, worldwide, sublicensable license in the aerospace and defense field to a granted U.S. patent covering autonomous, buoyancy-assisted transport of payloads across air and water NEWPORT BEACH, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- NorthStrive Defense Tech LLC ("NorthStrive Defense Tech"), a wholly owned subsidiary of PMGC Holdings Inc. (the "Company") (NASDAQ:ELAB), today announced entry into a binding term sheet for an exclusive, worldwide, sublicensable license, within the aerospace and defense technologies field, to a patented multi-domain drone payload technology covered by U.S. Patent No. 12,291,334. The technology enables an aerial vehicle to au

    6/8/26 7:31:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Signs Non-Binding Letter of Intent to Acquire Majority Stake in U.S.-Based Precision Machining Manufacturing Company Serving Aerospace, Space, Defense, and Semiconductor Markets

    The current Letter of Intent is non-binding and contemplates an all-cash acquisition of a 76% interest in the target companyTarget company is AS9100 compliant, ISO 9001:2015 certified, and ITAR registered, positioning it within highly regulated aerospace, space and defense supply chainsAcquisition advances PMGC's stated roll-up strategy in U.S.-based manufacturing amid reshoring and domestic supply chain tailwinds NEWPORT BEACH, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC", the "Company", "we" or "us"), a diversified public holding company currently executing a targeted roll-up strategy across U.S.-based manufacturing, today announced that it has ente

    6/1/26 7:31:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GB Capital Ltd. Co-Advises on the Acquisition of A&B Aerospace Inc.

    VANCOUVER, British Columbia, May 18, 2026 (GLOBE NEWSWIRE) -- GB Capital Ltd. ("GB Capital"), a strategic finance, advisory and management firm, today announced that it served as co-advisor to PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC") on PMGC's acquisition of A&B Aerospace, Inc. ("A&B Aerospace" or "A&B"), an AS9100D and ISO 9001:2015 certified precision machining and aerospace manufacturing company headquartered in Azusa, California. A&B Aerospace marks PMGC's fifth acquisition in the past twelve months and the latest milestone in the Company's targeted roll-up strategy in U.S.-based precision manufacturing. As disclosed by PMGC in its public announcement of the transaction (available he

    5/18/26 9:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Bensler Graydon

    4 - PMGC Holdings Inc. (0001840563) (Issuer)

    6/3/26 4:01:11 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Parry Jeffrey

    4 - PMGC Holdings Inc. (0001840563) (Issuer)

    6/3/26 8:09:25 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kovalyov George

    4 - PMGC Holdings Inc. (0001840563) (Issuer)

    6/2/26 8:10:59 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Leadership Updates

    Live Leadership Updates

    View All

    PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group

    NEWPORT BEACH, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the "Company" or "PMGC," "our," or "we") (NASDAQ:ELAB), a diversified holding company, is proud to announce its annual sponsorship of TCA Venture Group's ("TCA") Orange County network for 2025. As a Southern California Network Sponsor, PMGC is actively pursuing investments and M&A opportunities to strengthen its portfolio while fostering local business growth and expanding its market presence. TCA Venture Group (formerly known as Tech Coast Angels) is one of the largest and most active angel investor networks in the United States. With a history spanning over 25 years, TCA has been instrumental in funding early-s

    2/27/25 8:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

    Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme.Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific conferences and has consulted for Johnson & Johnson, Bayer, AstraZeneca and Pfizer, among other healthcare companies. NEWPORT BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the appointment of Orian Shirihai, MD, PhD, t

    7/30/24 9:00:26 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs

    NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. "We are honored to be forming a Scientific Advisory Board with renowned members that possess deep and complementary knowledge in metabolic diseases, obesity, weight management, muscle preservation and physical function in addition to significant experience in clinical

    6/14/24 9:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Financials

    Live finance-specific insights

    View All

    PMGC Holdings (NASDAQ: ELAB) Acquires A&B Aerospace, Inc.

    Precision machining and aerospace, defense manufacturing company contracted by long standing Tier 1 customers that include Boeing, Honeywell International Inc., and Moog Inc.*AS9100D and ISO 9001:2015 certified NEWPORT BEACH, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company"), a diversified holding company currently executing a targeted roll-up strategy in U.S.-based precision manufacturing companies, has acquired A&B Aerospace, Inc. ("A&B Aerospace" or "A&B"), Founded in 1948, A&B Aerospace is a precision machining and aerospace manufacturing company specializing in high-tolerance parts and assemblies for the aerospace industry. Headquart

    5/13/26 4:03:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NorthStrive Defense Tech Acquires Multi-Domain Drone Payload Technology Option for Defense and Commercial Applications

    NEWPORT BEACH, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- NorthStrive Defense Tech LLC ("NorthStrive Defense Tech"), a wholly-owned subsidiary of PMGC Holdings Inc. (the "Company") (NASDAQ:ELAB), today announced it has acquired rights to a novel drone technology through an exclusive option agreement ("Option Agreement") with a corporation. The Option Agreement provides NorthStrive Defense Tech with an exclusive option, within the aerospace and defense technologies field ("Field"), to get an exclusive license as to certain patent rights for U.S. Patent No. 12,291,334, covering a next-generation drone system designed to transport payloads across air and water environments. The option ("Opti

    4/6/26 7:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. Announces the Acquisition of SVM Machining, Inc.

    NEWPORT BEACH, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company"), a diversified public holding company announced that it has completed the acquisition of SVM Machining, Inc. ("SVM"). Founded in 1997 by Mark Serpa, SVM (aka Silicon Valley Manufacturing) is a Northern California-based ISO 9001:2015 Certified CNC precision machining and manufacturing services company serving medical, aerospace, biotech & pharmaceutical, semiconductor, and transportation markets. This transaction represents PMGC's third California based CNC machine shop acquisition to date, expanding PMGC's growing footprint in precision manufacturing and furthering its stra

    2/3/26 7:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    11/14/24 5:53:26 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    10/2/24 4:01:03 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    10/1/24 4:01:02 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care